Our board and management are as dedicated as our employees to drive Mabtech forward. A key feature is the efficient collaboration across all of our departments, facilitated by a shared view on customer satisfaction. 


Jan Wahlström

Jan Wahlström
Chief Executive Officer

CEO at Mabtech since May 2022. Prior to joining Mabtech Jan was CEO at Elos Medtech and prior to that CEO at Biolin Scientific. Jan has also served as Chairman of the board at Insplorion AB.


Torun Ekblad

Torun Ekblad, PhD
Chief Operating Officer

Holds a PhD in biotechnology from the Royal Institute of Technology in Stockholm, with a postdoc at the Karolinska Institute. Joined Mabtech and the R&D team in 2016 and was appointed COO in 2018.


Bartek Makower

Bartek Makower, PhD
Chief Scientific Officer

Holds a PhD in virology and immunology from the Karolinska Institute. Joined Mabtech and the R&D team 2002 and left for a Senior Scientist role at Swedish Orphan Biovitrum in 2015. Re-joined Mabtech as CSO in 2018.


Cecilia Driving

Cecilia Driving, BSc
Chief Financial Officer

CFO at Mabtech since January 2023. Prior to joining Mabtech Cecilia was CFO at Biovica International AB and has held several CFO positions in life-science, private equity, research and telecom companies. Cecilia serves as member of the board and chair of the audit committee of Ovzon AB and Embracer Group AB.


Jens Gertow

Jens Gertow, PhD
Chief Commercial Officer

Holds a PhD in therapeutic immunology from the Karolinska Institute, where he also did a postdoc at the Department of Medicine. Joined Mabtech in 2015 and was appointed CCO in 2018.


Kopek Nihlmark

Kopek Nihlmark, LicSc
Chief Quality Officer

Holds a Licentiate degree in immunology from the Karolinska Institute, where she worked as a university lecturer. Joined Mabtech in 2002 and was appointed Quality and Supply chain manager in 2004. Appointed CQO in 2010.


Christian Smedman

Christian Smedman, PhD
Chief Technology Officer

Holds a PhD in immunology from the Karolinska Institute (a joint Industrial PhD program between Mabtech and the Karolinska Institute). Joined Mabtech as Head of Sales & Marketing in 2013 and was appointed Chief Technology Officer and Head of IT in 2018.


Niklas Ahlborg

Niklas Ahlborg, PhD
Business Development Director

Holds a PhD in immunology from Stockholm University, with a post doc on malaria immunology from Edinburgh University. Joined Mabtech as Head of Research in 2000 and was CEO of Mabtech 2018-2022. Affiliated as Associate Professor at Stockholm University.



Lars Rasmussen

Lars Rasmussen
Chairman of the board

Chair of Coloplast & Lundbeck. Chair of the Life Science Council established by the Danish Government, Ex Chair of Lima and Igenomix (both formally EQT owned).

Isabel De Paoli

Isabel De Paoli
Partner EQT Healthcare Growth

Isabel joined EQT Partners in September 2021 based in Munich. Isabel worked almost 15 years for Merck KGaA. Lately as Chief Strategy Officer of Merck, she focused on long term portfolio, capital allocation and innovation strategies in the Pharmaceuticals and Life Science space as well as on transformation topics. Prior to that, Isabel has been with Permira and with The Boston Consulting Group. Isabel holds an M.Sc. degree in Process Engineering, with focus on Biotech, from the Technical University Hamburg-Harburg and a B.Sc. in Chemical Engineering from UNICAMP, Brazil.

Klaus Bischoff

Klaus-Reinhard Bischoff
Member of the board

Ex Head of Research Solutions at MilliporeSigma; the life science business of Merck, EVP Americas of Laboratory Business at Merck, and EVP of Lab Solutions at Merck

Mark Braganza

Mark Braganza
Partner EQT Healthcare Growth

Mark has Physiology and Medical degrees from the University of Cambridge. He led the development of diagnostics for stratification of cancer patients at Chiron Corp until its acquisition by Novartis. Mark has been an investor in healthcare and lifesciences companies since 2006 and is a Partner in the EQT Healthcare Growth advisory team.

Harry Klagsbrun

Harry Klagsbrun
Member of the board

Holds a B.A. in Journalism from Stockholm University, a M.Sc. in Business from the Stockholm School of Economics and an MBA from New York University. He has over 40 years of international experience as an advisor, investor and owner, with specialist expertise in corporate governance, corporate culture, company transformation and value creation, most recently from 15 years at EQT. Harry joined the Mabtech board in April 2024.

Peter Wrighton-Smith

Peter Wrighton-Smith
Member of the board

Holds a PhD in Medical Engineering from the University of Oxford and works as an independent advisor, director and investor in Life Science companies. Previously CEO of Oxford Immunotec (NASDAQ:OXFD) a T-cell immunology based diagnostics company and currently Member of the Board of Directors of biomodal and natcap.